Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
156.75B
Market cap156.75B
Price-Earnings ratio
23.87
Price-Earnings ratio23.87
Dividend yield
3.22%
Dividend yield3.22%
Average volume
1.77M
Average volume1.77M
High today
$292.00
High today$292.00
Low today
$288.26
Low today$288.26
Open price
$291.21
Open price$291.21
Volume
1.79M
Volume1.79M
52 Week high
$335.88
52 Week high$335.88
52 Week low
$253.30
52 Week low$253.30

AMGN News

TipRanks 16m
Amgen’s Latest Study on Sotorasib: A Strategic Move in Oncology

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 39m
Amgen’s Rocatinlimab Study: A Potential Game-Changer in Asthma Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 52m
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

Analyst ratings

48%

of 33 ratings
Buy
42.4%
Hold
48.5%
Sell
9.1%

More AMGN News

TipRanks 1h
Amgen’s New Pediatric Leukemia Study: A Potential Game-Changer?

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 1h
Amgen’s AMG 513 Study: A Potential Game-Changer in Obesity Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 2h
Amgen’s Promising New Study on Thyroid Eye Disease Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 2h
Amgen’s IMLYGIC® Study: A Closer Look at Safety and Market Implications

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 2h
Amgen’s UPLIZNA Pregnancy Safety Study: Key Insights for Investors

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 3h
Amgen’s New Pediatric Study: A Potential Game-Changer in Myasthenia Gravis Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

Nasdaq 5h
AMGN Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Amgen Inc (Symbol: AMGN) crossed below their 200 day moving average of $306.93, changing hands as low as $293.80 per share. Amg...

AMGN Makes Notable Cross Below Critical Moving Average

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.